James Revkin
MD, FACC, FACP, FCCP
Associate Clinical Professor; Attending Physician: Cardiology Fellows Clinic
Research & Publications
Biography
Research Summary
I have designed and conducted clinical research studies to establish the safety and efficacy of potential new drugs for the treatment and prevention of cardiovascular and metabolic diseases.
Extensive Research Description
My most current activities have been related to the design, conduct, and interpretation of data for large, industry sponsored, cardiovascular outcomes trials in the area of atherosclerosis, thrombosis, hypertension, heart failure, obesity, and diabetes. I am a subject matter expert in use of vascular imaging biomarkers to assess the clinical efficacy of pharmaceutical agents in slowing the progression of atherosclerosis.
Coauthors
Selected Publications
- The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis.Bonomi P, Crawford J, Dunne R, Roeland E, Smoyer K, Siddiqui M, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis. Journal Of Clinical Oncology 2023, 41: e24075-e24075. DOI: 10.1200/jco.2023.41.16_suppl.e24075.
- Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.Crawford J, Lubaczewski S, Tarachandani A, Harrington M, Weng Y, Qiu R, Collins S, Rossulek M, Revkin J. Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. Journal Of Clinical Oncology 2023, 41: tps12147-tps12147. DOI: 10.1200/jco.2023.41.16_suppl.tps12147.
- Abstract CT054: Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexiaCrawford J, Lubaczewski S, Tarachandani A, Harrington M, Weng Y, Qiu R, Collins S, Rossulek M, Revkin J. Abstract CT054: Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. Cancer Research 2023, 83: ct054-ct054. DOI: 10.1158/1538-7445.am2023-ct054.
- Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacyCrawford J, Calle R, Collins S, Weng Y, Lubaczewski S, Buckeridge C, Wang E, Harrington M, Tarachandani A, Rossulek M, Revkin J. Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy. Cancer Research 2023, 83: ct108-ct108. DOI: 10.1158/1538-7445.am2023-ct108.
- The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review.Dunne R, Bonomi P, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Clinical Oncology 2023, 41: 87-87. DOI: 10.1200/jco.2023.41.4_suppl.87.
- 1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature reviewBonomi P, Crawford J, Dunne R, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. 1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review. Annals Of Oncology 2022, 33: s1281. DOI: 10.1016/j.annonc.2022.07.1919.
- 1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapyRoeland E, Fintelmann F, Yang R, Tarasenko L, McRae T, Revkin J, Bonomi P. 1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy. Annals Of Oncology 2022, 33: s1125. DOI: 10.1016/j.annonc.2022.07.1396.
- ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitorSinger DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. American Heart Journal 2022, 249: 76-85. PMID: 35472303, DOI: 10.1016/j.ahj.2022.04.005.
- A RANDOMIZED CLINICAL TRIAL OF SCREENING FOR ATRIAL FIBRILLATION WITH A 14-DAY PATCH MONITOR: ANALYSIS OF ECG RECORDINGS FROM THE GUARD-AF STUDYSinger D, Atlas S, Go A, Lopes R, Lubitz S, McManus D, Revkin J, Mills D, Crosson L, Lenane J, Aronson R. A RANDOMIZED CLINICAL TRIAL OF SCREENING FOR ATRIAL FIBRILLATION WITH A 14-DAY PATCH MONITOR: ANALYSIS OF ECG RECORDINGS FROM THE GUARD-AF STUDY. Journal Of The American College Of Cardiology 2022, 79: 28. DOI: 10.1016/s0735-1097(22)01019-1.
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumabRidker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Investigators S. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Journal Of Clinical Lipidology 2018, 12: 958-965. PMID: 29685591, DOI: 10.1016/j.jacl.2018.03.088.
- Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabRidker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. New England Journal Of Medicine 2017, 376: 1517-1526. PMID: 28304227, DOI: 10.1056/nejmoa1614062.
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsRidker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/nejmoa1701488.
- Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsRidker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC, Investigators S. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal 2016, 178: 135-144. PMID: 27502861, DOI: 10.1016/j.ahj.2016.05.010.
- Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiencyAnker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani H, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal Of Heart Failure 2016, 18: 482-489. PMID: 27071916, DOI: 10.1002/ejhf.516.
- Rate of change in carotid intima–media thickness and vascular eventsBots ML, Taylor AJ, Kastelein JJ, Peters SA, Ruijter H, Tegeler CH, Baldassarre D, Stein JH, O’Leary D, Revkin JH, Grobbee DE. Rate of change in carotid intima–media thickness and vascular events. Journal Of Hypertension 2012, 30: 1690-1696. PMID: 22895014, DOI: 10.1097/hjh.0b013e32835644dc.
- Surrogate endpoints in randomized cardiovascular clinical trialsDomanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundamental & Clinical Pharmacology 2010, 25: 411-413. PMID: 20698890, DOI: 10.1111/j.1472-8206.2010.00865.x.
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsBarter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal Of Medicine 2007, 357: 2109-2122. PMID: 17984165, DOI: 10.1056/nejmoa0706628.
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialBots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, Investigators F. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. The Lancet 2007, 370: 153-160. PMID: 17630038, DOI: 10.1016/s0140-6736(07)61088-5.
- PO23-763 EFFICACY AND SAFETY OF COMBINATION TORCETRAPIB/ATORVASTATIN VERSUS ATORVASTATIN ALONE IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIARevkin J, Ose L, Marais A, Pretorius M, Viljoen J, Burgess L, Lan S, Thuren T, Shear C. PO23-763 EFFICACY AND SAFETY OF COMBINATION TORCETRAPIB/ATORVASTATIN VERSUS ATORVASTATIN ALONE IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA. Atherosclerosis Plus 2007, 8: 203. DOI: 10.1016/s1567-5688(07)71773-7.
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaKastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal Of Medicine 2007, 356: 1620-1630. PMID: 17387131, DOI: 10.1056/nejmoa071359.
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal Of Medicine 2007, 356: 1304-1316. PMID: 17387129, DOI: 10.1056/nejmoa070635.
- Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML. Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research And Opinion 2007, 23: 885-894. PMID: 17407645, DOI: 10.1185/030079907x182121.
- Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and FutureRevkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. Pharmacological Reviews 2007, 59: 40-53. PMID: 17329547, DOI: 10.1124/pr.59.1.1.
- Th-P16:262 The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapibBamberger M, Moya M, Durham K, Shear C, Nguyen T, Revkin J, Rothblat G. Th-P16:262 The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapib. Atherosclerosis Plus 2006, 7: 550. DOI: 10.1016/s1567-5688(06)82220-8.
- Th-P16:261 Enhanced LDL-C-lowering effect of torcetrapib when administered with atorvastatin to subjects with high baseline triglyceride levelsRevkin J, Shear C. Th-P16:261 Enhanced LDL-C-lowering effect of torcetrapib when administered with atorvastatin to subjects with high baseline triglyceride levels. Atherosclerosis Plus 2006, 7: 550. DOI: 10.1016/s1567-5688(06)82219-1.
- Th-P16:260 Inhibition of CETP by torcetrapib raises HDL-C and lowers LDL-C independent of gender or baseline HDL-C levelsRevkin J, Durham K, Shear C, Nguyen T. Th-P16:260 Inhibition of CETP by torcetrapib raises HDL-C and lowers LDL-C independent of gender or baseline HDL-C levels. Atherosclerosis Plus 2006, 7: 550. DOI: 10.1016/s1567-5688(06)82218-x.
- W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart diseaseNissen S, Tardif J, Crowe T, Thuren T, Shear C, Revkin J. W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. Atherosclerosis Plus 2005, 6: 116. DOI: 10.1016/s1567-5688(05)80456-8.
- W10-P-018 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemiaKastelern J, Bots M, Riley W, Evans G, Meijer R, Revkin J, Raszewska J, Shear C, Thuren T. W10-P-018 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis Plus 2005, 6: 51-52. DOI: 10.1016/s1567-5688(05)80205-3.
- W10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemiaBots M, Riley W, Evans G, Kastelein J, Revkin J, Thuren T, Shear C, Nguyen T. W10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia. Atherosclerosis Plus 2005, 6: 48. DOI: 10.1016/s1567-5688(05)80191-6.
- Laparoscopic Surgery as an Option for Gallstones in Cardiac Transplant Candidates and RecipientsBegos D, Lee F, Franco K, Baldwin J, Revkin J, Modlin I. Laparoscopic Surgery as an Option for Gallstones in Cardiac Transplant Candidates and Recipients. 1996, 22: 118-126. DOI: 10.1159/000425278.
- Optimal timing and indications for cholecystectomy in cardiac transplant patientsBegos D, Franco K, Baldwin J, Lee F, Revkin J, Modlin I. Optimal timing and indications for cholecystectomy in cardiac transplant patients. World Journal Of Surgery 1995, 19: 661-667. PMID: 7676717, DOI: 10.1007/bf00294752.
- Heart Failure: Basic Science and Clinical Aspects, edited by Judith K. Gwathmey, G. Maurice Briggs, Paul D. Allen, Marcel Dekker, Inc., New York (1993) 736 pages, illustrated, $195.00 ISBN: 9–8247–8772–2Revkin J. Heart Failure: Basic Science and Clinical Aspects, edited by Judith K. Gwathmey, G. Maurice Briggs, Paul D. Allen, Marcel Dekker, Inc., New York (1993) 736 pages, illustrated, $195.00 ISBN: 9–8247–8772–2. Clinical Cardiology 1994, 17: 282-283. DOI: 10.1002/clc.4960170514.
- Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplastyYoung L, Jaffe C, Revkin J, McNulty P, Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. The American Journal Of Cardiology 1990, 65: 986-990. PMID: 2327360, DOI: 10.1016/0002-9149(90)91001-m.